Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Elekta AB ( ($SE:EKTA.B) ) has shared an announcement.
Elekta AB reported a 3% increase in net sales at constant exchange rates for the first quarter of 2025/26, driven by strong performance in Europe. Despite challenges such as FX effects and tariffs impacting margins, the company improved its cash flow significantly by SEK 529 million due to better working capital management. The company achieved several commercial milestones, including FDA clearance for its Leksell Gamma Knife and a significant deal with the University of Texas Southwestern. Elekta expects continued growth in net sales over the fiscal year, despite anticipated challenges in the US and China markets.
The most recent analyst rating on ($SE:EKTA.B) stock is a Hold with a SEK53.00 price target. To see the full list of analyst forecasts on Elekta AB stock, see the SE:EKTA.B Stock Forecast page.
More about Elekta AB
Elekta AB operates in the medical technology industry, focusing on innovative solutions for radiation therapy and radiosurgery. The company is known for its linear accelerators and software suites, such as Elekta Evo and Elekta ONE, which are designed to enhance cancer treatment capabilities.
Average Trading Volume: 1,054,999
Technical Sentiment Signal: Sell
Current Market Cap: SEK18.63B
Learn more about EKTA.B stock on TipRanks’ Stock Analysis page.